EZH2 and non-small cell lung carcinoma: These findings suggested that hsa_circ_0020123-miR-144- ZEB1/EZH2 axis is critical for NSCLC progression, which indicates that hsa_circ_0020123 is a promising therapeutic for NSCLC treatment.